gms | German Medical Science

11th Malaria Meeting

Malaria Group / Section Antiparasitic Chemotherapy of the Paul-Ehrlich-Society (PEG e. V.) in cooperation with the German Society for Tropical Medicine and International Health (DTG e. V.) and the German Society for Parasitology (DGP e. V.)

08.11. - 09.11.2013, Aachen

Introduction to Medicines for Malaria Venture (MMV)

Meeting Abstract

Search Medline for

  • Jörg J. Möhrle - Medicines for Malaria Venture (MMV)

11th Malaria Meeting. Aachen, 08.-09.11.2013. Düsseldorf: German Medical Science GMS Publishing House; 2014. Doc13mal10

doi: 10.3205/13mal10, urn:nbn:de:0183-13mal101

Published: January 29, 2014

© 2014 Möhrle.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



Apart from Artemisinin Combination Therapies (ACTs) there are relatively few effective treatments for Plasmodium falciparum malaria and only one complete treatment for Plasmodium vivax.

This talk will summarize the work of Medicines for Malaria Venture (MMV) and its mission to reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating delivery of new, effective and affordable antimalarial drugs.

MMV manages a significant antimalarial pipeline and this has been strengthened in recent years with the delivery of new artemisinin combination therapies, promising new clinical candidates and early stage discovery projects. The talk will explain both the challenges that need to be overcome and the strategy adopted to eradicate the disease, including definitions of target product profiles necessary for asexual blood stage cures (including single dose combination treatment), transmission blocking, vivax and chemoprotection.